Skip to main content
Erschienen in: Wiener Medizinische Wochenschrift 3-4/2015

01.02.2015 | main topic

Cathepsin K-Inhibitoren: präklinische und klinische Daten

verfasst von: Dr. Marion Gamsjäger, MD, Prim. Univ. Prof. Dr. Heinrich Resch

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 3-4/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Cathepsin K ist eine Cysteinproteinase und somit ein essentielles Enzym in der Degradation von Kollagen Typ I. Es wird fast ausschließlich in Osteoklasten exprimiert. Aufgrund des physiologischen Mechanismus stellt diese Protease einen pharmakologischen Angriffspunkt für die Entwicklung neuer Medikamente in der Osteologie dar. In den letzten Jahrzehnten wurde intensiv daran geforscht, hochwirksame, selektive und oral einnehmbare Cathepsin K-Inhibitoren zu entwickeln. Im Gegensatz zu Balicatib und Relacatib, deren Weiterentwicklung wegen kutaner Nebenwirkungen bei relativ geringer Spezifität eingestellt wurde, wendete sich die Forschung den spezifischeren Cathepsin K-Inhibitoren Odanacatib (ODN) und ONO-5334 zu. So hebt Odanacatib bei postmenopausalen Frauen sehr deutlich die Knochenmineraldichte und hemmt die Knochenresorption. Als Voraussetzung für die Weiterentwicklung konnte in einer Langzeituntersuchung die Sicherheit und Wirksamkeit des Medikaments bestätigt werden. Jedoch nehmen nach dessen Absetzen Knochenresorption und Knochenmasseverlust wieder zu. Eine Phase III Frakturpräventionsstudie an postmenopausalen Frauen mit Osteoporose befindet sich derzeit in der Endphase.
Literatur
1.
Zurück zum Zitat Bromme D, Lecaille F. Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opin Investig Drugs. 2009;18(5):585–600.CrossRefPubMedCentralPubMed Bromme D, Lecaille F. Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opin Investig Drugs. 2009;18(5):585–600.CrossRefPubMedCentralPubMed
2.
Zurück zum Zitat Bromme D, Okamoto K, Wang BB, et al. Human cathepsin O2, a matrix protein-degrading cysteineprotease expressed in osteoclasts. Functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme. J Biol Chem. 1996 Jan 26;271(4):2126–32.CrossRefPubMed Bromme D, Okamoto K, Wang BB, et al. Human cathepsin O2, a matrix protein-degrading cysteineprotease expressed in osteoclasts. Functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme. J Biol Chem. 1996 Jan 26;271(4):2126–32.CrossRefPubMed
3.
Zurück zum Zitat Bossard MJ, Tomaszek TA, Thompson SK, et al. Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification. J Biol Chem. 1996;271(21):12517–24.CrossRefPubMed Bossard MJ, Tomaszek TA, Thompson SK, et al. Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification. J Biol Chem. 1996;271(21):12517–24.CrossRefPubMed
4.
Zurück zum Zitat Kafienah W, Bromme D, Buttle DJ, et al. Human cathepsin K cleaves native type I and II collagens at the N-terminal end of the triplehelix. Biochem J. 1998;331(3):727–32.PubMedCentralPubMed Kafienah W, Bromme D, Buttle DJ, et al. Human cathepsin K cleaves native type I and II collagens at the N-terminal end of the triplehelix. Biochem J. 1998;331(3):727–32.PubMedCentralPubMed
5.
Zurück zum Zitat Garnero P, Borel O, Byrjalsen I, Ferreras M, et al. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem. 1998;273(48):32347–52.CrossRefPubMed Garnero P, Borel O, Byrjalsen I, Ferreras M, et al. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem. 1998;273(48):32347–52.CrossRefPubMed
6.
Zurück zum Zitat Goto T, Yamaza T, Tanaka T. Cathepsins in the osteoclast. J Electron Microsc (Tokyo). 2003;52(6):551–8.CrossRef Goto T, Yamaza T, Tanaka T. Cathepsins in the osteoclast. J Electron Microsc (Tokyo). 2003;52(6):551–8.CrossRef
7.
Zurück zum Zitat Gelb BD, Shi GP, Chapman HA, et al. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science. 1996;273(5279):1236–8.CrossRefPubMed Gelb BD, Shi GP, Chapman HA, et al. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science. 1996;273(5279):1236–8.CrossRefPubMed
8.
Zurück zum Zitat Saftig P, Hunziker E, Wehmeyer O, et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA. 1998;95(23):13453–8.CrossRefPubMedCentralPubMed Saftig P, Hunziker E, Wehmeyer O, et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA. 1998;95(23):13453–8.CrossRefPubMedCentralPubMed
9.
Zurück zum Zitat Gowen M, Lazner F, Dodds R, et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res. 1999;14(10):1654–63.CrossRefPubMed Gowen M, Lazner F, Dodds R, et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res. 1999;14(10):1654–63.CrossRefPubMed
10.
Zurück zum Zitat Rood JA, Van Horn S, Drake FH, et al. Genomic organization and chromosome localization of the human cathepsin K gene (CTSK). Genomics. 1997;41(2):169–76.CrossRefPubMed Rood JA, Van Horn S, Drake FH, et al. Genomic organization and chromosome localization of the human cathepsin K gene (CTSK). Genomics. 1997;41(2):169–76.CrossRefPubMed
11.
Zurück zum Zitat Lecaille F, Bromme D, Lalmanach G. Biochemical properties and regulation of cathepsin K activity. Biochimie. 2008;90(2):208–26.CrossRefPubMed Lecaille F, Bromme D, Lalmanach G. Biochemical properties and regulation of cathepsin K activity. Biochimie. 2008;90(2):208–26.CrossRefPubMed
12.
Zurück zum Zitat Xia L, Kilb J, Wex H, et al. Localization of rat cathepsin K in osteoclasts and resorption pits: inhibition of bone resorption and cathepsin K-activity by peptidyl vinyl sulfones. Biol Chem. 1999;380(6):679–87.CrossRefPubMed Xia L, Kilb J, Wex H, et al. Localization of rat cathepsin K in osteoclasts and resorption pits: inhibition of bone resorption and cathepsin K-activity by peptidyl vinyl sulfones. Biol Chem. 1999;380(6):679–87.CrossRefPubMed
13.
Zurück zum Zitat Sassi ML, Eriksen H, Risteli L, et al. Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. Bone. 2000;26(4):367–73.CrossRefPubMed Sassi ML, Eriksen H, Risteli L, et al. Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. Bone. 2000;26(4):367–73.CrossRefPubMed
14.
Zurück zum Zitat Mano H, Yuasa T, Kameda T, et al. Mammalian mature osteoclasts as estrogen target cells. Biochem Biophys Res Commun. 1996;223(3):637–42.CrossRefPubMed Mano H, Yuasa T, Kameda T, et al. Mammalian mature osteoclasts as estrogen target cells. Biochem Biophys Res Commun. 1996;223(3):637–42.CrossRefPubMed
15.
Zurück zum Zitat Furuyama N, Fujisawa Y. Regulation of collagenolytic cysteine protease synthesis by estrogen in osteoclasts. Steroids. 2000;65(7):371–8.CrossRefPubMed Furuyama N, Fujisawa Y. Regulation of collagenolytic cysteine protease synthesis by estrogen in osteoclasts. Steroids. 2000;65(7):371–8.CrossRefPubMed
16.
Zurück zum Zitat Parikka V, Lehenkari P, Sassi ML, et al. Estrogen reduces the depth of resorption pits by disturbing the organic bone matrix degradation activity of mature osteoclasts. Endocrinology. 2001;142(12):5371–8.CrossRefPubMed Parikka V, Lehenkari P, Sassi ML, et al. Estrogen reduces the depth of resorption pits by disturbing the organic bone matrix degradation activity of mature osteoclasts. Endocrinology. 2001;142(12):5371–8.CrossRefPubMed
17.
Zurück zum Zitat Fujisaki K, Tanabe N, Suzuki N, et al. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells. Life Sci. 2007;80(14):1311–8.CrossRefPubMed Fujisaki K, Tanabe N, Suzuki N, et al. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells. Life Sci. 2007;80(14):1311–8.CrossRefPubMed
18.
Zurück zum Zitat Zhao Q, Jia Y, Xiao Y. Cathepsin K: a therapeutic target for bone diseases. Biochem Biophys Res Commun. 2009;380(4):721–3.CrossRefPubMed Zhao Q, Jia Y, Xiao Y. Cathepsin K: a therapeutic target for bone diseases. Biochem Biophys Res Commun. 2009;380(4):721–3.CrossRefPubMed
19.
Zurück zum Zitat Falgueyret JP, Desmarais S, Oballa R, et al. Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J Med Chem. 2005;48(24):7535–43.CrossRefPubMed Falgueyret JP, Desmarais S, Oballa R, et al. Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J Med Chem. 2005;48(24):7535–43.CrossRefPubMed
20.
Zurück zum Zitat Desmarais S, Black WC, Oballa R, et al. Effect of cathepsin k inhibitor basicity on in vivo off-target activities. Mol Pharmacol. 2008;73(1):147–56.CrossRefPubMed Desmarais S, Black WC, Oballa R, et al. Effect of cathepsin k inhibitor basicity on in vivo off-target activities. Mol Pharmacol. 2008;73(1):147–56.CrossRefPubMed
21.
Zurück zum Zitat Peroni A, Zini A, Braga V, et al. Drug-induced morphea: report of a case induced by balicatib and review of the literature. J Am Acad Dermatol. 2008;59(1):125–9.CrossRefPubMed Peroni A, Zini A, Braga V, et al. Drug-induced morphea: report of a case induced by balicatib and review of the literature. J Am Acad Dermatol. 2008;59(1):125–9.CrossRefPubMed
22.
Zurück zum Zitat Kumar S, Dare L, Vasko-Moser JA, et al. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. Bone. 2007;40(1):122–31.CrossRefPubMed Kumar S, Dare L, Vasko-Moser JA, et al. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. Bone. 2007;40(1):122–31.CrossRefPubMed
23.
Zurück zum Zitat Perez-Castrillon JL, Pinacho F, De Luis D, et al. Odanacatib, a new drug for the treatment of osteoporosis: review of the results in postmenopausal women. J Osteoporos. 2010 : 401581. doi:10.4061/2010/401581. Perez-Castrillon JL, Pinacho F, De Luis D, et al. Odanacatib, a new drug for the treatment of osteoporosis: review of the results in postmenopausal women. J Osteoporos. 2010 : 401581. doi:10.4061/2010/401581.
24.
Zurück zum Zitat Gauthier JY, Chauret N, Cromlish W, Desmarais S, et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett. 2008;18(3):923–8.CrossRefPubMed Gauthier JY, Chauret N, Cromlish W, Desmarais S, et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett. 2008;18(3):923–8.CrossRefPubMed
25.
Zurück zum Zitat Costa AG, Cusano NE, Silva BC, et al. Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol. 2011;7:447–56. doi:10.1038/nrrheum.2011.77.CrossRefPubMed Costa AG, Cusano NE, Silva BC, et al. Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol. 2011;7:447–56. doi:10.1038/nrrheum.2011.77.CrossRefPubMed
27.
Zurück zum Zitat Stoch SA, Zajic S, Stone J, et al. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. Clin Pharmacol Ther. 2009;86(2):175–82.CrossRefPubMed Stoch SA, Zajic S, Stone J, et al. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. Clin Pharmacol Ther. 2009;86(2):175–82.CrossRefPubMed
28.
Zurück zum Zitat Bone HG, McClung MR, Roux C, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res. 2010;25(5):937–47.PubMed Bone HG, McClung MR, Roux C, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res. 2010;25(5):937–47.PubMed
29.
Zurück zum Zitat Nagase S, Ohyama M, Hashimoto Y, et al. Pharmacodynamic effects on biochemical markers of bone turnover and pharmacokinetics of the cathepsin K Inhibitor, ONO-5334, in an ascending multiple-dose, phase 1 study. Br J Clin Pharmacol. 2012;74(6):959–70.CrossRefPubMedCentralPubMed Nagase S, Ohyama M, Hashimoto Y, et al. Pharmacodynamic effects on biochemical markers of bone turnover and pharmacokinetics of the cathepsin K Inhibitor, ONO-5334, in an ascending multiple-dose, phase 1 study. Br J Clin Pharmacol. 2012;74(6):959–70.CrossRefPubMedCentralPubMed
30.
Zurück zum Zitat Eisman JA, Bone HG, Hosking DJ, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res. 2011;26(2):242–51.CrossRefPubMed Eisman JA, Bone HG, Hosking DJ, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res. 2011;26(2):242–51.CrossRefPubMed
31.
Zurück zum Zitat Greenspan SL, Emkey RD, Bone HG, et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of boneloss after discontinuation of treatmentof postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002;137(11):875–83.CrossRefPubMed Greenspan SL, Emkey RD, Bone HG, et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of boneloss after discontinuation of treatmentof postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002;137(11):875–83.CrossRefPubMed
32.
Zurück zum Zitat Sornay-Rendu E, Garnero P, Munoz F, et al. Effect of withdrawal of hormone replacement therapy on bonemass and bone turnover: the OFELY study. Bone. 2003;33(1):159–66.CrossRefPubMed Sornay-Rendu E, Garnero P, Munoz F, et al. Effect of withdrawal of hormone replacement therapy on bonemass and bone turnover: the OFELY study. Bone. 2003;33(1):159–66.CrossRefPubMed
33.
Zurück zum Zitat Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43(2):222–9.CrossRefPubMed Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43(2):222–9.CrossRefPubMed
34.
Zurück zum Zitat Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med. 2005;353(6):555–65.CrossRefPubMed Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med. 2005;353(6):555–65.CrossRefPubMed
35.
Zurück zum Zitat Bauer DC. Discontinuation of odanacatib and other osteoporosis treatments: here today and gone tomorrow? J Bone Miner Res. 2011;26(2):239–41. doi:10.1002/jbmr.335.CrossRefPubMed Bauer DC. Discontinuation of odanacatib and other osteoporosis treatments: here today and gone tomorrow? J Bone Miner Res. 2011;26(2):239–41. doi:10.1002/jbmr.335.CrossRefPubMed
36.
Zurück zum Zitat Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–65.CrossRefPubMed Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–65.CrossRefPubMed
37.
Zurück zum Zitat Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809–22.CrossRefPubMed Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809–22.CrossRefPubMed
38.
Zurück zum Zitat Anderson M, Gendrano I, Liu C, Jeffers S, et al. Odanacatib in older men. J Clin Endocrinol Metab. 2014;99(2):552–60.CrossRefPubMed Anderson M, Gendrano I, Liu C, Jeffers S, et al. Odanacatib in older men. J Clin Endocrinol Metab. 2014;99(2):552–60.CrossRefPubMed
39.
Zurück zum Zitat Bonnick S, Villiers T, Odio A, et al. Odanacatib in women previously treated with alendronate. J Clin Endocrinol Metab. 2013;98(12):4727–35.CrossRefPubMed Bonnick S, Villiers T, Odio A, et al. Odanacatib in women previously treated with alendronate. J Clin Endocrinol Metab. 2013;98(12):4727–35.CrossRefPubMed
40.
Zurück zum Zitat Langdahl B, Binkley N, Bone H, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J Bone Miner Res. 2012;27(11):2251–8. doi:10.1177/1759720×13490860.CrossRefPubMed Langdahl B, Binkley N, Bone H, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J Bone Miner Res. 2012;27(11):2251–8. doi:10.1177/1759720×13490860.CrossRefPubMed
41.
Zurück zum Zitat Cusick T, Chen CM, Pennypacker BL, et al., Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. J Bone Miner Res. 2012;27(3):524–37.CrossRefPubMed Cusick T, Chen CM, Pennypacker BL, et al., Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. J Bone Miner Res. 2012;27(3):524–37.CrossRefPubMed
42.
Zurück zum Zitat Jayakar RY, Cabal A, Szumiloski J, et al. Evaluation of high-resolution peripheral quantitative computed tomography, finite element analysis and biomechanical testing in a pre-clinical model of osteoporosis: a study with odanacatib treatment in the ovariectomized adult rhesus monkey. Bone. 2012;50(6):1379–88. doi:10.1016/j.bone.2012.03.017CrossRefPubMed Jayakar RY, Cabal A, Szumiloski J, et al. Evaluation of high-resolution peripheral quantitative computed tomography, finite element analysis and biomechanical testing in a pre-clinical model of osteoporosis: a study with odanacatib treatment in the ovariectomized adult rhesus monkey. Bone. 2012;50(6):1379–88. doi:10.1016/j.bone.2012.03.017CrossRefPubMed
43.
Zurück zum Zitat Masarachia PJ, Pennypacker BL, Pickarski M, et al. Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys. J Bone Miner Res. 2012;27(3):509–23. doi:10.1016/j.bone.2013.06.008CrossRefPubMed Masarachia PJ, Pennypacker BL, Pickarski M, et al. Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys. J Bone Miner Res. 2012;27(3):509–23. doi:10.1016/j.bone.2013.06.008CrossRefPubMed
44.
Zurück zum Zitat Cheung AM, Majumdar S, Brixen KR, et al. Effects of odanacatib on the radius and tibia of postmenopausal women: improvements in bone geometry, microarchitecture and estimated bone strength. J Bone Miner Res. 2014;29:1786–94. doi:10.1002/jbmr.2194CrossRefPubMed Cheung AM, Majumdar S, Brixen KR, et al. Effects of odanacatib on the radius and tibia of postmenopausal women: improvements in bone geometry, microarchitecture and estimated bone strength. J Bone Miner Res. 2014;29:1786–94. doi:10.1002/jbmr.2194CrossRefPubMed
45.
Zurück zum Zitat Engelke K, Fürst T, Dardzinski B, et al. Odanacatib treatment affects trabecular and cortical bone in the femur of postmenopausal women – results of a 2-year placebo-controlled trial. J Bone Miner Res. 2014 June 4. doi: 10.1002/jbmr.2292 Engelke K, Fürst T, Dardzinski B, et al. Odanacatib treatment affects trabecular and cortical bone in the femur of postmenopausal women – results of a 2-year placebo-controlled trial. J Bone Miner Res. 2014 June 4. doi: 10.1002/jbmr.2292
Metadaten
Titel
Cathepsin K-Inhibitoren: präklinische und klinische Daten
verfasst von
Dr. Marion Gamsjäger, MD
Prim. Univ. Prof. Dr. Heinrich Resch
Publikationsdatum
01.02.2015
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 3-4/2015
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-014-0336-3

Weitere Artikel der Ausgabe 3-4/2015

Wiener Medizinische Wochenschrift 3-4/2015 Zur Ausgabe